Section Abstract Introduction Methods Results Discussion Conflict of Interest Acknowledgment Funding Sources References
Clinical Research
Vitamin D levels and depression in type 2 diabetes mellitus patients: a cross-sectional study
pISSN: 0853-1773 • eISSN: 2252-8083
https://doi.org/10.13181/mji.oa.237005 Med J Indones. 2023;32:177–82
Received: June 09, 2023
Accepted: November 14, 2023
Published online: December 14, 2023
Authors' affiliation:
Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Corresponding author:
Rudi Putranto
Division of Psychosomatic and Palliative Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital,
Jalan Diponegoro No. 71, Central Jakarta 10430, DKI Jakarta, Indonesia
Telp/Fax: +62-21-3196052
E-mail: putranto.rudi09@gmail.com
Background
The prevalence of type 2 diabetes mellitus (T2DM) is increasing and commonly accompanied by comorbidities, such as depression. Vitamin D levels have been associated with T2DM and depression although the mechanism is uncertain. This study aimed to compare vitamin D levels between patients with T2DM with and without depression in the Indonesian community, where such research is rare.
Methods
This cross-sectional study was conducted at Cipto Mangunkusumo Hospital. The participants who met the inclusion criteria on an outpatient basis were screened for depression using the Beck Depression Inventory-II (BDI-II) questionnaire and then divided into 2 groups: patients with T2DM with (BDI-II ≥14) and without (BDI-II <14) depression. Both groups were examined for vitamin D levels using the ELISA method, and an analysis of the mean difference between both groups was performed.
Results
Of 60 patients, 23 (38%) experienced depression. The median vitamin D levels were 21.8 ng/ml (IQR 14.9–26.6) in the depression group and 26.5 ng/ml (IQR 23.96–34.08) in the non-depression group (p = 0.001). After performing multivariate analysis with confounding variables, the adjusted OR of variables (sex, sun exposure score, and body mass index) was 1.123 (95% CI: 1.003–1.259; p = 0.045).
Conclusions
Vitamin D levels were significantly lower in patients with T2DM with depression. Future studies should be carried out to determine the benefits of vitamin D supplementation in patients with T2DM with depression and their pathophysiology.
Keywords
depression, type 2 diabetes mellitus, vitamin D level
Patients with type 2 diabetes mellitus (T2DM) are at risk for depression, with a higher prevalence rate (11–17.6%) than the general population (3–4%).1,2 Furthermore, 41% of patients with T2DM experience depression.2 Theoretically, depression could be exacerbated by diabetes treatment. Diabetes causes anatomical changes in the brain, including cerebral atrophy and lacunar infarctions, blood flow variations (hypoperfusion and hyperperfusion), and an increased risk of depression.3 Depression in patients with T2DM greatly influences medication adherence, diet control, and blood glucose monitoring, thus increasing the treatment cost and lowering the quality of the prognosis of the disease course.2–4 Despite the condition, using tricyclic antidepressants might impair glucose metabolism in patients with diabetes and increase their body weight.5
Vitamin D is a fat-soluble vitamin commonly involved in bone and calcium metabolism and known for its anti-inflammatory and immunomodulatory properties. Various studies have shown that vitamin D deficiency correlates with various diseases, such as DM, cardiovascular diseases, cancer, autoimmune diseases, and depression.6–8 Vitamin D plays a crucial role in regulating insulin levels and maintaining proper glucose metabolism, which is essential for the prevention and management of diabetes. Furthermore, individuals with depression tend to have higher blood sugar levels, indicating a potential connection between depression and T2DM. Therefore, addressing vitamin D deficiency could positively impact mental health and prevent T2DM.6,7
The association between vitamin D and depression has been reported in several studies, including a systematic review by Ju et al,9 which reported that an increase in vitamin D levels by 10 ng/ml was associated with improved depressive symptoms and reduced depression risk. Lower levels of vitamin D have also been reported in patients with depression than in the controls.10,11 It has been proposed that hypovitaminosis D may contribute to depression. Vitamin D metabolites protect neuronal integrity by upregulating neurotrophic factors (nerve growth factor, neurotrophin [NT]-3, and NT-4) in the hippocampus and neocortex. Furthermore, vitamin D affects inflammatory pathways (downregulating autoimmune processes, releasing proinflammatory cytokines, and increasing anti-inflammatory pathways through vitamin D receptor-mediated gene transcription), which are associated with depression.10
Notably, vitamin D levels have not been compared between patients with and without depression who have T2DM in Indonesia. To address this knowledge gap, the present study aimed to investigate the relationship between vitamin D levels and T2DM in patients with and without depression. This would provide a better understanding of the association between vitamin D deficiency and the co-occurrence of T2DM and depression.
METHODS
This cross-sectional study was conducted at the Metabolic Endocrine and Diabetes Clinic of the Department of Internal Medicine, Cipto Mangunkusumo Hospital, Jakarta, Indonesia, between July and August 2022. This study analyzed data collected from interviews and laboratory tests of the included participants.
Selection and characteristics of the participants
Patients with T2DM aged ≥18 years (adult) who visited the clinic were enrolled in this study. The sample was obtained through consecutive sampling until the number of participants reached the required size. Patients with a known history of comorbidities, such as cancer, autoimmune disease, and stages 4 and 5 chronic kidney disease, and pregnant and lactating women were excluded from this study. Patients who received vitamin D supplementation, antidepressants, or immunosuppressant therapy and who declined to participate in this study were also excluded.
Study procedure
Eligible outpatients with T2DM were screened for depression by conducting an interview using the Beck Depression Inventory-II (BDI-II) questionnaire and weekly sun exposure scoring, as reported by Husna.12 The skin area exposed to sunlight each day for a week was multiplied by the old score (length of exposure) to determine the sun exposure score. Subsequently, history-taking and physical examinations were conducted. Based on the BDI-II scoring results, the participants were divided into two groups: patients with T2DM with (BDI-II score ≥14) and without (BDI-II score <14) depression. The Indonesian version of the BDI-II questionnaire was validated by Ginting et al,13 with good specificity and sensitivity. Patients were then prepared for serum vitamin D analysis using laboratory analysis. A 3 ml blood sample from a peripheral venipuncture was assessed for 25-hydroxyvitamin D (25[OH]D) serum at the Cipto Mangunkusumo Laboratory using the enzyme-linked immunosorbent assay (ELISA) method.14 The procedure was performed only once without any therapeutic intervention or any other invasive procedure to minimize hemorrhage after blood puncture.
Laboratory analysis
Serum vitamin D tests were performed using a sandwich ELISA. Two antibodies were used to capture the target antigens. The test was performed using the DiaSino® 25(OH)D Total ELISA Kit (DiaSino Laboratories Co., Ltd, China). The microplate was then prepared for absorbance reading using a light wave of 450 nm in the microplate reader 30 min after the addition of the stop solution. The absorbance was extrapolated to a reference value based on the manufacturer’s instructions.
Statistical analysis
Statistical analyses were performed using Microsoft Excel 2016 (Microsoft Corp., USA) and SPSS software version 20.0 (IBM Corp., USA). Categorical data are presented as frequencies and percentages, whereas numerical data are presented as mean (standard deviation [SD]) for normally distributed data or median (min–max) for data with non-normal distribution. Data normality was determined using the Kolmogorov–Smirnov test. The comparison or significant difference in the 25(OH)D of each independent and confounding variable was analyzed using bivariate analysis, utilizing an independent t-test for normally distributed data and the Mann–Whitney U test for data with non-normal distribution. Data are presented as mean, SD, and p-value using a 95% confidence interval [CI] (statistical significance was set at p<0.05). Confounding variables were analyzed using multivariate logistic regression analysis.
Ethical clearance
This study was approved by the Ethics Committee of the Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital (No. KET-348/UN2.F1/ETIK/PPM.00.02/2022). The participants were informed of the study procedure and signed an informed consent form prior to data extraction.
RESULTS
Of the 93 patients enrolled in this study, 60 were finally included (Figure 1). Participants’ baseline characteristics are presented in Table 1.
Figure 1. Participants’ enrollment flowchart. BDI-II=Beck Depression Inventory-II; CKD=chronic kidney disease; T2DM=type 2 diabetes mellitus
Table 1. Baseline characteristics of the participants
Age and body mass index (BMI) were similar between patients with T2DM with and without depression. However, those who had depression were predominantly females. Higher median sun exposure scores and lower vitamin D levels were observed in the depression group (Table 2).
Table 2. Multivariate analysis of depression in patients with T2DM
The lower the vitamin D level, the higher the risk of depression (crude odds ratio [OR]: 1.107; 95% CI: 1.031–1.189; p = 0.005). This remained significant after adjusting for sex, sun exposure score, and BMI (adjusted OR: 1.123; 95% CI: 1.003–1.259; p = 0.045).
DISCUSSION
This study found a significantly increased risk of depression in patients with T2DM with vitamin D deficiency. Vitamin D levels were lower in the depression group than in the control group. In contrast, Westra et al15 found no correlation between vitamin D deficiency and the risk of depression in patients with T2DM. Other studies have shown different vitamin D levels in patients with obesity experiencing depression compared with those without depression.16 The results are consistent with other studies on depression in patients with several comorbidities, such as liver disease and perinatal or postpartum depression.17–25 Furthermore, Wang et al26 found a median vitamin D level of 10.2 ng/ml (interquartile range [IQR]: 7.6–15.2) among patients with T2DM with depression, compared with 14.6 ng/ml (IQR: 10.7–19.8) among those without depression. No significant associations were found between vitamin D levels and the duration of T2DM, therapy, or sociodemographic factors.
Regarding the confounding variables in the present study, there were no significant differences in age and BMI. However, significant differences were observed in sex and sun exposure. The depression group comprised females predominantly, which is consistent with the study of Salk et al,22 in which a 3 times higher risk of depression was observed in females than in males, particularly in the teenage age group (12–16 years old). Females are more prone to depression because of higher stress, cognitive instability owing to hormonal imbalance, and a higher risk of comorbidities of anxiety and somatic symptoms, particularly during peripartum and postpartum periods.23,24 However, Al Qusaibi et al25 found an insignificant incidence between males and females.
Sun exposure is a significant confounding factor that increases serum vitamin D levels and lowers the proportion of vitamin D deficiency.27,28 Notably, sun exposure might also affect depressive symptoms and other mental disorders because it has a dose-response effect, with lower exposure correlating with worsening cognitive status.29 This finding is consistent with that of other reports on the efficacy of sun exposure in improving depressive symptoms and quality of life.30,31 This phenomenon might be explained by an increase in anti-inflammatory cytokines, which might explain the improvement in mood progression. In addition, sun exposure is correlated with increased cortisol levels and circadian rhythm regulation, thereby improving mood and depressive symptoms.32–34
Diabetes is associated with vitamin D deficiency. The significance of vitamin D in sustaining accurate insulin release by pancreatic beta cells in patients with diabetes involves the establishment of insulin resistance. Beta cells can overcome this resistance by releasing more insulin, thus preventing hyperglycemia. However, when hyperactivity increases, the cells exhibit increased Ca2+ levels and reactive oxygen species signaling, leading to cell death and diabetes. Vitamin D deficiency contributes to initial insulin resistance and subsequent onset of diabetes caused by beta cell apoptosis. Vitamin D prevents inflammation, which is a major factor in insulin resistance.35 The use of vitamin D supplementation has also been reported to positively impact mental health and depressive symptoms in patients, particularly those with insufficient vitamin D.36–38 According to several studies, vitamin D supplementation may reduce depression in patients with T2DM.39–42
This study had several limitations. First, the study design did not cover the causes of depression or vitamin D deficiency. Second, this study did not include the diet consumption variable despite the probable increase in vitamin D based on a suitable diet. However, several studies have reported non-significant differences owing to diet differences in vitamin D levels.43,44
In conclusion, this study reported significantly lower vitamin D levels in patients with T2DM with depression. Future studies should be conducted to determine the benefits of vitamin D supplementation in patients with T2DM with depression and their pathophysiology.
Conflict of Interest
The authors affirm no conflict of interest in this study.
Acknowledgment
None.
Funding Sources
None.
REFERENCES
Copyright @ 2023 Authors. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are properly cited. For commercial use of this work, please see our terms at http://mji.ui.ac.id/journal/index.php/mji/copyright.
mji.ui.ac.id